QUANTITY | PRIC PER pellet | SAVE AMOUNT |
---|---|---|
10 to 19 | EUR 2.00 /pellet | 0% |
20 to 29 | EUR 1.80 /pellet | 10% |
30 to 49 | EUR 1.70 /pellet | 15% |
50 to 99 | EUR 1.50 /pellet | 25% |
100 to 249 | EUR 1.20 /pellet | 40% |
250 to 499 | EUR 1.00 /pellet | 50% |
500 + | EUR 0.70 /pellet | 65% |
POPULAR PRODUCT
Many customers bought this product recently.
Pyrazolam is a novel depressant substance classified within the benzodiazepine family. Originally developed by Hoffman-La Roche in the 1970s, it was later "rediscovered" and introduced to the market as a research chemical in 2012. This compound has gained attention for its unique pharmacological profile and subjective effects.
Users of pyrazolam report a range of subjective effects, including sedation, anxiety suppression, muscle relaxation, disinhibition, and euphoria. Notably, pyrazolam is said to produce comparatively greater levels of anxiety suppression than sedation and euphoria when compared to other benzodiazepines, making it particularly appealing for those seeking relief from anxiety without excessive sedation.
Pyrazolam is characterized by its distinctive chemical structure, which includes a benzene ring fused to a diazepine ring—a seven-membered ring containing two nitrogen atoms at positions R1 and R4. A bromine atom is attached at R7, while a 2-pyridine ring substitutes the bicyclic core at R6. Additionally, pyrazolam features a 1-methylated triazole ring that is fused to and incorporates R1 and R2 of its diazepine ring. This structural configuration classifies pyrazolam as a member of the triazolobenzodiazepines, a subclass of benzodiazepines denoted by the suffix "-zolam."
The pharmacological effects of pyrazolam are primarily mediated through its interaction with the GABAA receptors in the central nervous system. Benzodiazepines, including pyrazolam, enhance the effects of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. This modulation leads to the sedative and calming effects associated with pyrazolam.
Interestingly, the anticonvulsant properties of benzodiazepines may also be attributed to their binding to voltage-dependent sodium channels, in addition to their action on GABA receptors. Pyrazolam exhibits selectivity for the α2 and α3 receptor subtypes of the GABAA receptor, which may contribute to its unique effects. Unlike many other benzodiazepines, pyrazolam is excreted unchanged by the body, meaning it does not interact with liver enzymes, potentially making it safer for individuals with compromised liver function.
The physical effects of pyrazolam include sedation, dizziness, motor control loss, muscle relaxation, and respiratory depression. However, it is generally less sedating than other benzodiazepines unless taken at higher doses.
The cognitive effects of pyrazolam can be categorized into several components that intensify with dosage. Users often describe the headspace induced by pyrazolam as one of mild sedation coupled with significant anxiety suppression. Common cognitive effects include:
Delusions of sobriety refer to the false belief that one is sober despite clear evidence of cognitive impairment, which can occur at higher doses.
The recommended dosages for pyrazolam vary based on individual sensitivity and experience. The following dosage categories are commonly recognized:
The total duration of effects typically ranges from 5 to 8 hours, with an onset time of approximately 10 to 15 minutes following oral administration.
Pyrazolam represents a unique addition to the benzodiazepine class, offering distinct effects that may be beneficial for individuals seeking anxiety relief. Its novel pharmacological profile, including its relatively greater anxiety suppression compared to sedation, makes it a subject of interest in both research and potential therapeutic applications. However, as with any psychoactive substance, caution is advised due to the risks of dependence, tolerance, and potential side effects associated with benzodiazepines. Further research is necessary to fully understand the implications of pyrazolam use, its long-term effects, and its safety profile in various populations.
Pyrazolam 4mg Pellets is for research use only and not intended for human consumption!
Pyrazolam 4mg Pellets stock last updated at: April 2025